Additionally, it’s likely that some proportion of patients in this cohort harbored an ESR1 mutation - a known resistance mechanism of breast cancer to AI’s with a prevalence reported as high as 53% or greater in MBC24, though this was not assayed in this trial. This evidence concerns the gene ESR1 and breast carcinoma.